This cohort study assesses patterns of treatment failure and postrecurrence outcomes among patients with head and neck squamous cell carcinoma after chemoradiotherapy using contemporary radiotherapy techniques.
This cohort study examines magnetic resonance imaging or ultrasonography plus mammography in screening for a second breast cancer in women 50 years or younger who underwent breast conservation therapy.
This secondary analysis of data from a randomized clinical trial of women treated with tamoxifen vs no systemic therapy and followed up for 2 decades investigates if a multigene classifier is associated with indolent behavior of invasive breast cancers.
This pooled analysis of data from 2 phase 3 trials of nivolumab therapy in treatment-naive patients with advanced melanoma assesses the safety and efficacy of continuing treatment beyond progression.
This randomized clinical trial examines the effect of the addition of EGFR inhibition to chemoradiation on survival outcomes for patients with esophageal cancer.
This multiple-cohort study assesses a robust, individualized immune signature for estimating prognosis in patients with early-stage nonsquamous non–small cell lung cancer.
This randomized clinical trial compares the incidence and time to onset of grade 2 or higher hand-foot syndrome in patients receiving pyridoxine vs placebo and identifies biomarkers predictive of hand-foot syndrome.
This cohort study evaluates the genomic profile of patients with small-bowel adenocarcinoma compared with colorectal cancer and gastric carcinoma.
This study evaluated the use of abiraterone acetate plus prednisone in men with metastatic prostate cancer.
This secondary analysis of a phase 3 randomized clinical trial investigates the role of tumor-infiltrating lymphocytes in predicting outcomes in patients with HER2-positive metastatic breast cancer randomized to antibody vs small molecule–based anti-HER2 therapy.
This cohort study assessed the survival impact of second primary malignant neoplasms (SMPs) in adolescents and young adults compared with that of children and older adults with the same SPMs.
This case-control study using 2 cohorts attempts to identify the genetic variants associated with cisplatin-induced ototoxic effects in adult patients with testicular cancer.
This cross-sectional study investigates whether history of previous clinical breast examination is associated with earlier presentation and/or earlier cancer stage at diagnosis among women in Peru.
This study analyzes Medicare claims data associated with end-of-life hospitalization care and costs for elderly patients with a malignant brain tumor.
This cross-sectional survey study examines financial distress and cost expectations among patients with cancer presenting for anticancer therapy.
This review investigates recent advances in the understanding of the genetics of small cell carcinoma of the urinary bladder and the potential implications in diagnosis, prognosis, and treatment.
A woman in her 60s with a history of metastatic breast cancer presented with a 3-month history of a progressive, asymptomatic cutaneous eruption of nontender discrete erysipeloid plaques on her chest and back. What is your diagnosis?
This Viewpoint examines possible unintended harms of the new American Society of Clinical Oncology guidelines that state that all patients with advanced cancer receive palliative care from interdisciplinary specialty palliative care teams.
This Viewpoint examines the conclusions of the ProtecT randomized clinical trial and argues that, instead of radical therapy, appropriate patients for active surveillance should be chosen and active surveillance strategies optimized to avoid the small increased risk of distant metastasis seen in ProtecT.
This Viewpoint examines the potential use of machine learning to improve imaging-based breast cancer screening performance and associated patient outcomes.
This Viewpoint discusses the need to balance speed of approval and safety of drugs in the US Food and Drug Administration’s process of drug approval.
This Viewpoint discusses why the market for biosimilars and the cost savings related to their use have remained smaller than expected in the United States and suggests ways to rectify this situation.